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Van der Woude syndrome (VWS) is a genetic syndrome that leads to typical phenotypic
traits, including lower lip pits and cleft lip/palate (CLP). The majority of VWS-affected
patients harbor a pathogenic variant in the gene encoding for the transcription factor
interferon regulatory factor 6 (IRF6), a crucial regulator of orofacial development,
epidermal differentiation and tissue repair. However, most of the underlying mechanisms
leading from pathogenic IRF6 gene variants to phenotypes observed in VWS remain
poorly understood and elusive. The availability of one VWS individual within our cohort of
CLP patients allowed us to identify a novel VWS-causing IRF6 variant and to functionally
characterize it. Using VWS patient-derived keratinocytes, we reveal that most of the
mutated IRF6_VWS transcripts are subject to a non-sense-mediated mRNA decay
mechanism, resulting in IRF6 haploinsufficiency. While moderate levels of IRF6_VWS
remain detectable in the VWS keratinocytes, our data illustrate that the IRF6_VWS
protein, which lacks part of its protein-binding domain and its whole C-terminus, is
noticeably less stable than its wild-type counterpart. Still, it maintains transcription
factor function. As we report and characterize a so far undescribed VWS-causing IRF6
variant, our results shed light on the physiological as well as pathological role of IRF6
in keratinocytes. This acquired knowledge is essential for a better understanding of the
molecular mechanisms leading to VWS and CLP.
Keywords: Van der Woude syndrome, IRF6, cleft lip/palate, non-sense-mediated mRNA decay, haploinsuffiency,
epidermal differentiation
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INTRODUCTION
Craniofacial morphogenesis represents one of the most intricate
developmental processes of our body. It involves several
spatiotemporally regulated gene regulatory networks (GRN) that
control cellular mechanisms, such as differentiation, migration,
proliferation, and apoptosis, driving outgrowth, patterning, and
fusion of facial structures. This immense complexity makes the
formation of the craniofacial components highly susceptible to
dysregulations that can lead to anomalies, such as cleft lip/palate
(CLP) (Wilkie and Morriss-Kay, 2001).
CLP is a deformity resulting from failure of the facial
processes to grow or fuse properly during embryogenesis
(Deshpande and Goudy, 2019). With an average incidence rate
of one in 750 newborns, CLP belongs to the most frequent
human birth anomalies worldwide (Kousa and Schutte, 2016).
Although this malformation is not a major cause of mortality
in developed countries, it still poses an enormous psychological,
social, and economic burden for cleft-affected patients, their
families, and society as a whole (Wehby and Cassell, 2010).
Furthermore, even after the need for the young CLP patients
to endure several corrective surgeries, they may still experience
complications and consequences of their anomalies, including
problems with speech, hearing, wound healing, scar and tissue
contractures, and facial asymmetries (Van Beurden et al., 2005;
Hortis-Dzierzbicka et al., 2012).
CLP is etiologically very complex and heterogeneous,
involving a combination of genetic and environmental risk
factors, and it can occur either in syndromic or non-syndromic
form (Mossey et al., 2009). While non-syndromic CLP represents
the majority of cases and lacks any phenotypic features outside
of the orofacial region, syndromic individuals present with
additional anomalies outside of the clefting area. To date,
numerous genetic risk factors have been identified and associated
with orofacial clefting (Gritli-Linde, 2007; Juriloff and Harris,
2008; Dixon et al., 2011; Bush and Jiang, 2012). However, the
individual cause and the underlying mechanism is only known
for the minority of CLP cases (Meng et al., 2009).
Van der Woude syndrome (VWS; OMIM # 119300) is
one of the most common syndromic forms of orofacial
clefts, accounting for 2% of all CLP cases (Rizos and
Spyropoulos, 2004; Little et al., 2009). VWS is inherited as
an autosomal dominant condition with high penetrance and
variable expressivity (Peyrard-Janvid et al., 2005) associated
with one or more of the following characteristics: lower lip
pits/fistulae, CLP, or submucous cleft palate (Van Der Woude,
1954). Recent studies have further identified a higher risk of
wound healing complications following surgical cleft repair and
a thicker epidermis with more proliferating keratinocytes in
VWS patients when compared to non-syndromic children (Jones
et al., 2010; Hixon et al., 2016). Hence, GRNs seem to be
involved in the pathogenesis of VWS that orchestrate craniofacial
morphogenesis, tissue repair, and epidermal differentiation. So
far, three genes have been causatively linked to VWS: (1) Loss-of-
function mutations in Interferon Regulatory Factor 6 (IRF6) are
responsible for 72% of VWS cases, but pathogenic IRF6 variants
are also found in the more severe Popliteal Pterygium syndrome
(PPS; OMIM # 119500) (Kondo et al., 2002) and in non-
syndromic CLP (Zucchero et al., 2004); (2) dominant-negative
variants of Grainyhead-like transcription factor 3 (GRHL3) have
been reported in 5% of VWS patients not having IRF6 mutations
(Peyrard-Janvid et al., 2014); (3) a rare pathogenic missense
variant in NME/NM23 Nucleoside Diphosphate Kinase 1 (NME1)
has been recently identified in IRF6 and GRHL3 mutation-
negative VWS individuals (Parada-Sanchez et al., 2017).
IRF6 is a transcription factor regulating the balance between
immature ectoderm differentiation and proliferation during
craniofacial morphogenesis. Irf6-deficient mice display a
thickened and disorganized oral epithelium, reduced skin barrier
function, and premature aberrant oral adhesions, resulting in
orofacial clefts (Ingraham et al., 2006; Richardson et al., 2006).
While IRF6-truncating heterozygous variants are often found
in VWS patients (de Lima et al., 2009), detailed descriptions of
genotype-phenotype correlations in VWS are still missing.
Here, we describe a novel heterozygous VWS-causing IRF6
frameshift variant c.961_965delGTGTAinsC/p.(Val321Profs∗15)
affecting the highly conserved protein-binding domain
SMIR/IAD of IRF6 [SMAD/IRF (SMIR) or interferon association
domain (IAD) (Eroshkin and Mushegian, 1999)]. Using VWS
and non-syndromic CLP patient-derived keratinocytes, we
show that the IRF6_VWS transcript undergoes an incomplete
non-sense-mediated RNA decay (NMD) process leading to IRF6
haploinsufficiency. Additionally, we reveal that the IRF6_VWS
protein is less stable than its wild-type (wt) counterpart, but that
it maintains its function as a transcription factor. Using primary
patient cells as well as over-expression systems, we present a
thorough functional characterization of a novel VWS-causing
IRF6 variant and elucidate how the specific variant affects the
phenotype of keratinocytes.
MATERIALS AND METHODS
Ethics Statement
This work was performed according to the Ethical Principles
for Medical Research Involving Human Subjects as defined by
the World Medical Association (WMA Declaration of Helsinki -
Ethical principles for medical research involving human
subjects. Available at: https://www.wma.net/policies-post/
wma-declaration-of-helsinki-ethical-principles-for-medical-
research-involving-human-subjects). Isolation of human cleft
lip- as well as control tissue-derived keratinocytes and their
analyses for this study have been approved by the Kantonale
Ethikkommission of Bern, Switzerland (protocol number:
2017-01394). Informed written consent was obtained from the
patient’s parents.
Cell Culture
Cleft lip tissue samples were obtained from three to seven
months old patients undergoing primary corrective surgery at
the Children’s Hospital, University of Bern. Clinical assessment
and surgeries were all performed by two highly experienced
clinicians (I.S. and G.C. LS). In addition, we included three
healthy control biopsies: lip tissue from a four-year-old child
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sustaining a lip laceration; foreskin from a two-year-old boy
undergoing circumcision; forehead skin from an 18-month-old
infant experiencing a traumatic incident.
Patient-derived cells were isolated from the tissue as described
previously using the explant culture system (Degen et al., 2018).
After their isolation, keratinocytes were cultured in keratinocyte
serum-free medium (KSFM, Gibco, Thermo Fisher Scientific,
Lucerne, Switzerland) supplemented with 25 µg/ml bovine
pituitary extract, 0.2 ng/ml epidermal growth factor (EGF), and
CaCl2 to a final Ca2+ concentration of 0.4 mM, as described
elsewhere (Degen et al., 2012). To maintain healthy cells,
keratinocyte cultures reaching 40% confluency were re-fed daily
with 1:1 medium (1:1 vol/vol Ca2+-free Dulbecco’s modified
Eagle’s medium (DMEM) with complete KSFM). Experiments
using primary cells were all performed with cultures from the
second to fourth passage. Each of the keratinocyte primary cell
cultures originating from individual donors represents a mixture
of cells that grew out of multiple explants. All cells were tested for
mycoplasma contamination prior to freezing.
The immortalized oral mucosal keratinocytes OKF6/TERT2
were grown in KSFM as described elsewhere (Dickson et al.,
2000). The commercially available human keratinocyte cell line
HaCaT (#300493) and the human embryonic kidney cell line
HEK293 (#300192; both from CLS cell line service, Eppelheim,
Germany) were cultured in DMEM containing 10% fetal calf
serum (FCS, Sigma-Aldrich, St. Louis, MO, United States) and
1 x Pen/Strep solution (Gibco, Thermo Fisher Scientific).
Details and characteristics of all the cells used in this study are
summarized in Table 1.
Immunofluorescence
For cell staining, cells were grown in 35 mm dishes containing
four separate wells (Greiner Bio-One, Frickenhausen, Germany).
Cells were washed twice with phosphate-buffered saline (PBS)
before fixation in 4% paraformaldehyde (PFA) for 15 min
at room temperature. Afterward, fixed cells were washed
three times in PBS, permeabilized in 0.1% Triton-X-100
for 5 min and incubated with primary antibody for 2 h
at room temperature. After three PBS rinses, cells were
incubated, light-protected, with fluorescent-labeled secondary
antibodies (Molecular Probes, Thermo Fisher Scientific) and/or
tetramethylrhodamine (TRITC)-phalloidin (Sigma-Aldrich) for
1 h, rinsed with PBS and coverslip-mounted with Vectashield
Mounting Medium containing DAPI (Vector Laboratories,
Burlingame, CA, United States). Cells were examined under
an Olympus BX-51 phase/fluorescence microscope (Olympus
Life Science Solutions Tokyo, Japan) equipped with a xenon
lamp (X-Cite, series 120PC Q, Lumen Dynamics, Mississauga,
Canada), and fluorescence filters U-MWIBA3 for AlexaFluor
488 and U-MNUA2 for DAPI (Olympus Life Science Solutions).
Images were captured by a ProgRes CT3 camera with
ProgRes CapturePro software (Jenaoptik, Jena, Germany),
using a 20x/0.5 objective. Primary antibodies used: anti-myc
(clone 9E10, Abcam, Cambridge, United Kingdom), anti-IRF6
(clone 14B2C16, BioLegend, San Diego, CA, United States),
and anti-E-Cadherin (20874-1-AP, Proteintech, Manchester,
United Kingdom). TA
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For IRF6 localization and quantification, linescan plots were
performed using the ImageJ software version 1.50f1 (NIH,
Bethesda, MD, United States). Briefly, a line, spanning an entire
cell, was drawn and the gray intensities along the line (through
the cell) were plotted for the DAPI (blue) as well as for the IRF6
channel (green).
3D-Cultures
To generate 3D-skin models using CLP patient-derived
keratinocytes, the protocol from CELLnTEC (CELLnTEC
advanced cells systems AG, Bern, Switzerland) was used. Briefly,
2 × 105 cells were seeded in 400 µl KSFM into polycarbonate
inserts (0.4 µm pore size, 12 mm diameter, Nunc, Thermo Fisher
Scientific) placed in 60 mm tissue culture dishes, immediately
followed by the addition of 11 ml of KSFM outside the inserts. To
confirm confluency, one insert from each culture was stained two
days after seeding with the staining kit (CnT-ST-100, CELLnTEC)
and observed with brightfield microscopy. If the monolayer was
confluent, keratinocyte differentiation was induced in the
parallel culture by the replacement of KSFM with 3D Barrier
Medium (CnT-PR-3D, CELLnTEC) inside and outside of the
insert (equal medium level) overnight. The insert was then lifted
to the air-liquid interface by carefully removing the medium
inside the insert and replenishing the outside medium with
fresh 3D Barrier Medium up to the level of the membrane
(approximately 3.2 ml for a p60 culture dish). Keratinocytes were
cultured for 15 days at 37◦C and 5% CO2 with medium change
every other day.
To analyze the skin models, 3D-cultures were fixed overnight
at 4◦C in 4% PFA. Membranes were cut out of the inserts, placed
between two biopsy pads in embedding cassettes, and stored
in 0.1 M sodium cacodylate buffer at 4◦C before proceeding
for paraffin embedding and sectioning on a Reichert-Jung
microtome (Leica Microsystems, Heerbrugg, Switzerland). Slides
containing 5 µm thick paraffin sections were deparaffinized and
rehydrated through xylene, ethanol, and deionized H2O, stained
with hematoxylin and eosin (H&E) or anti-Loricrin antibody
(PA5-30583, Thermo Fisher Scientific). Immunostainings and
microscopy were performed as described above for the cells.
For the quantification of Loricrin-positive areas the ImageJ
software was used.
Next Generation Sequencing (NGS)
For NGS, VWS patient DNA was extracted from EDTA-blood
using the Prepito DNA Blood600 Kit (PerkinElmer, Waltham,
MA, United States). Targeted exome capture sequencing
was performed using the TruSight One sequencing Kit
on a MiSeq Sequencing system (Illumina, San Diego, CA,
United States) according to the manufacturer’s instructions.
Sequencing data were analyzed using CLC Workbench (Qiagen,
Hilden, Germany) using GRCh37hg19 as reference genome. The
candidate variant was verified by Sanger sequencing.
Pathogenic variants in the known VWS-associated genes
IRF6 (NM_006147.4), GRHL3 (NM_198173), and NME1
(NM_198175) have been excluded in the CLP patient-derived
1https://imagej.nih.gov/ij/download.html
cells CLP1-CLP4 by whole exome sequencing (WES) using the
Twist human core exome Kit including RefSeq spike in (TWIST
Biosciences, San Francisco, CA, United States) on a NextSeq 500
instrument (Illumina).
RNA Extraction, cDNA Synthesis, and
Quantitative Real-Time PCR (qPCR)
Analysis
Total RNA was isolated from cells using the innuPREP RNA
Mini kit (Analytik Jena AG, Jena, Germany) according to
their standard protocol for eukaryotic cells. RNA quality
and concentration were assessed using a Nanodrop 2000c
instrument (Thermo Fisher Scientific). RNA was stored at−80◦C
until further use.
First strand cDNA was synthesized from 500 ng total RNA
using the M-MLV Reverse Transcriptase (Promega, Dübendorf,
Switzerland) and Oligo(dT)15 Primer (Promega). mRNA levels
were analyzed and quantified by qPCR using GoTaq R© qPCR
Master Mix (Promega) on a QuantStudio 3 instrument (Applied
Biosystems, Thermo Fisher Scientific). Relative RNA expression
was calculated using the 11CT method, normalizing values to
GAPDH within each sample.
Sequences of the qPCR primers (Supplementary Table S1)
were either taken from the PrimerBank database2 or from the
NCBI primer designing tool3. All qPCR primer pairs were tested
for specificity and efficiency using cDNA standard curves.
Non-sense-mediated mRNA Decay
(NMD) Analysis
VWS-, non-syndromic CLP (CLP1), and healthy control
lip-derived keratinocytes (lip) were cultured either in KSFM
or in KSFM including the NMD inhibitors Puromycin for
4 h (100 µg/ml, Sigma-Aldrich) or cycloheximide for 4 h
(CHX, 100 µg/ml, Sigma-Aldrich). RNAs were isolated
from both cell lines and conditions and cDNAs synthesized.
cDNAs were used as templates for qPCR analyses using
specific primers recognizing IRF6_VWS, total IRF6, and
IRF6wt, respectively. In addition, VWS- and CLP1- derived
cDNAs were used as templates for PCR amplifications of a
389 bp IRF6 fragment (spanning exon 7–9) encompassing
the specific IRF6_VWS variant at position 961 base pairs (bp)
using the primers 5′-GAGCAGGTCAAATTCCCAGG-3′/5′-
ATCCGAGCCACTACTGGAATGAC-3′. PCR amplicons were
run on an agarose gel, DNA extracted, purified, and sequenced
using the primers mentioned above. Chromatograms were
analyzed using the DNA sequencing software Chromas 2.6.64.
Immunoblotting
Whole cell extracts were prepared in RIPA buffer [10 mM
Tris–Cl (pH 8.0), 1 mM EDTA, 0.1% sodium deoxycholate,
0.1% sodium dodecyl sulfate (SDS), 1% NP40, 140 mM NaCl]
supplemented with cOmpleteTM Mini Protease Inhibitor
2www.pga.mgh.harvard.edu
3www.ncbi.nlm.nih.gov/tools/primer-blast
4www.technelysium.com.au
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Cocktail and PhosSTOPTM EASYpack (both from Roche,
Sigma-Aldrich) just prior to use. Protein concentrations of
extracts were measured using the BCA Protein Assay Kit (Pierce,
Thermo Fisher Scientific) following the standard protocol.
20 µg of protein lysate in loading buffer (62.6 mM Tris–HCl,
pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue)
containing 100 mM dithiothreitol (DTT) were boiled for 5 min
at 95◦C and separated by SDS-PAGE under reducing conditions
and blotted on to nitrocellulose membranes (Amersham,
Sigma-Aldrich). Following the transfer, membranes were
stained in 0.1% amido black solution (MERCK, Schaffhausen,
Switzerland) to control for blotting efficiency. After blocking
the membranes for 1 h at room temperature in Tris-buffered
saline (TBS, pH 7.4) containing 0.05% Tween-20 and 5%
skim milk powder (Sigma-Aldrich), they were incubated
over-night with primary antibody at 4◦C on a rocking
platform. Membranes were washed three times in TBS-
Tween and incubated for 1 h with peroxidase-conjugated
anti-rabbit/mouse IgG in TBS-Tween/5% milk at room
temperature. After washing in TBS-Tween, blots were developed
using SuperSignal West Dura or Super Signal West Pico
PLUS Chemiluminescent Substrate (both from Thermo Fisher
Scientific) and scanned by a Chemi Premium Imager Instrument
(VWR, Darmstadt, Germany). Primary antibodies used: anti-
myc (clone 9E10, Abcam, Cambridge, United Kingdom),
anti-IRF6 (clone 14B2C16, BioLegend, San Diego, CA,
United States), anti-vinculin (V9131, Sigma-Aldrich), and
anti-KLF4 (11880-1-AP, Proteintech).
Some immunoblots were analyzed densitometrically using the
ImageJ software. Briefly, the intensity of each protein band was
normalized to the vinculin band intensity of the same extract in
the same experiment.
Cloning of the IRF6 Constructs
To generate a myc-tagged IRF6 expression plasmid (IRF6wt),
cDNA was synthesized from total RNA extracted from HaCaT
cells and PCR was performed on the cDNA using the GoTaq
Flexi DNA Polymerase (Promega) with the following primers:
5′-AGGCGATCGCCATGGCCCTCCACCCCCGCAGAG-3′/5′-
AGACGCGTTTCCGAGTTTACAGTGAAGTGCAG-3′. Pri-
mers contained an AsiSI (forward) and a MluI restriction site
(reverse), respectively. This allowed the directional cloning into
the mammalian expression plasmid pCMV6-A-Puro (Origene,
Rockville, MD, United States) containing a myc tag.
For the generation of the specific myc-tagged IRF6_VWS
expression plasmid (c.961_965 delGTGTA ins C), the
IRF6wt plasmid was used as DNA template for a
PCR with the primer pair 5′-AGGCGATCGCCATGG
CCCTCCACCCCCGCAGAG-3′ (same as above)/5′-GACTC
GAGGGTTGGGAGCAACAAGTGATGGGGCACATGGCCCA
GACCAGGCTTGCACTGGCACAGCCTGATGGC-3′ (Xho I
restriction site), allowing directional cloning into the
above mentioned pCMV6 plasmid. All constructs were
sequence-verified using the sequencing primers CMV (5′-
CGCAAATGGGCGGTAGGCGTG-3′) and XL39 (5′-ATTAGG
ACAAGGCTGGTGGG-3′).
Cell Transfections and Treatments
Transient transfections were performed in 35 mm tissue culture
dishes with cells at 60–70% confluence using ViaFect (Promega)
following the manufacturer’s protocol with 2 µg DNA and
6 µl transfection reagent diluted in OptiMEM (Thermo Fisher
Scientific). Six hours after transfection, the transfection mix
was removed, and the cells were washed once before being
replenished with fresh medium. Cells were analyzed 24 or 48 h
post-transfection.
To assess IRF6 stability, 20 µg/ml of the protein translation
inhibitor CHX (Sigma-Aldrich) was added to the cells 24 h
after transfection. Thereafter, proteins were extracted at the
indicated time points and immunoblotted. Proteasome inhibition
was induced by 10 µM MG132 (Sigma-Aldrich) for eight hours.
When the double treatment MG132/CHX was applied, MG132
was added to the cells 30 min prior to CHX.
Luciferase Reporter Assay
2.5 × 105 HEK293 cells/ml were seeded into wells of a
flat-bottom 96-well plate the day before transfection. On the
next morning, cells were transfected as previously described
using 90 ng of IFN-Beta_pGL3 [a gift from Nicolas Manel
(Addgene plasmid # 102597; http://n2t.net/addgene:102597;
RRID:Addgene_102597)], 10 ng of pRL-TK (wild-type Renilla
luciferase gene for normalization; Promega), and 100 ng of
pCMV6-IRF6wt or pCMV6-IRF6_VWS, respectively. Luciferase
assays were performed using the Dual-Glo luciferase assays
system (Promega) according to their manual. Firefly and Renilla
luminescence were read on a Tecan InfinitePro2000 plate reader
(Tecan Group Ltd., Männedorf, Switzerland) and the ratio of
firefly:renilla luminescence was calculated for each sample and
normalized to the reporter-only control.
Statistical Analysis
Experiments were performed at least three times in multiple
replicates. Data were analyzed using GraphPad InStat Software,
version 3.05. Data are represented as means± standard deviation
(SD). Multiple comparisons were performed using one-way
analysis of variance (ANOVA) with Tukey’s post hoc test. Values
of p ≤ 0.05 were considered significant.
Data Availability
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
RESULTS
VWS Patient-Derived Keratinocytes
Display Defects in Terminal
Differentiation
Our previous findings suggested that some of the genetic
predispositions causing VWS might lead to deficiencies in
terminal differentiation of keratinocytes in vitro (Degen et al.,
2018). To extend these results, we investigated more thoroughly
the genetic and phenotypic particularities of VWS-derived
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lip keratinocytes (VWS) compared to non-syndromic CLP-
(CLP1-3) and healthy control-derived lip keratinocytes (lip,
Table 1). The characteristic of cell growth, cell size as well
as the morphology of the cell colonies were similar in all
of the keratinocyte cultures tested as evidenced by brightfield
and immunostainings for F-actin (phalloidin) and E-Cadherin
(Figure 1A). Next, we wanted to assess their differentiation
potential in confluent 2D cultures. As the lip represents
a mucosa-skin transition zone, we analyzed differentiation
markers of both tissue types, skin and mucosa, by qPCR.
We detected lower RNA levels of the differentiation markers
Loricrin (LOR) and Filaggrin (FLG) (skin) as well as of
Keratin 4 (KRT4) and Keratin 13 (KRT13) (mucosa) in VWS
keratinocytes compared to the CLP and healthy control lip cells
(Figure 1B). In contrast, Keratin 14 (KRT14) and Keratin 19
(KRT19), markers mainly expressed in the basal proliferating
layer of keratinized epithelium and oral mucosa, respectively
(Lindberg and Rheinwald, 1989), did not significantly differ
among the keratinocyte cultures (Figure 1B). We further
confirmed a reduced potential to terminally differentiate in
VWS keratinocytes using 3D organotypic skin models. While
there were no obvious differences visible in H&E stainings of
the 3D skin models among the cultures tested, we detected a
significantly reduced area of LOR-positive keratinocytes in the
FIGURE 1 | (A) Brightfield pictures (top row) and immunofluorescent stainings (bottom row) for E-Cadherin (green) and F-actin (phalloidin, red) of four patient- and
one healthy control-derived lip keratinoyte colonies reveal no morphological differences between the VWS patient- and three non-syndromic CLP patient-derived cell
cultures (CLP1-3) and the healthy control (lip). Scale bar: 50 µm. (B) qPCR analyses of several differentiation markers in VWS-derived keratinocytes (black bar)
compared to three non-syndromic CLP-derived keratinocytes (CLP1-3, white bars) and to healthy lip keratinocytes (lip, gray bar). VWS keratinocytes express lower
levels of the differentiation markers LOR and FLG (non-mucosal) as well as of KRT4 and KRT13 (mucosal) compared to non-syndromic (CLP1-3) and healthy control
lip keratinocytes. In contrast, expression of KRT14 and KRT19, markers of the corresponding basal layers, is similar among the cell cultures tested. Note that our
primary lip-derived keratinocytes represent a mixture of both mucosal as well as non-mucosal cells. *p ≤ 0.05 vs. VWS. (C) Hematoxylin and eosin (H&E) staining of
3D-skin models using VWS, CLP1, and CLP2 keratinocytes (top row). Scale bar: 50 µm. Staining for LOR indicates differentiation deficiencies of VWS keratinocytes
when compared to the others. Scale bar: 50 µm. A larger stretch of the 3D-skin model produced by VWS-keratinocytes is shown at the bottom. Scale bar: 50 µm.
Dotted lines represent the upper edge of the inserts. (D) Quantification of the LOR-positive area in 3D-skin models reveals a significant difference between VWS and
non-syndromic cultures. ∗p ≤ 0.05 vs. VWS.
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FIGURE 2 | (A) Schematic representation of the IRF6 gene and the novel pathogenic variant IRF6_VWS c.961_965delGTGTAinsC (bottom). The IRF6 gene is
located on chromosome 1 (reverse strand), contains nine exons and two crucial domains, the DNA-Binding domain (blue) and the SMAD/IRF (SMIR)/interferon
association domain (IAD) (orange). The newly identified gene variant affects exon 7 at base pair (bp) 961, which is indicated by the red box. Light gray boxes:
untranslated exons/regions; dark gray boxes: translated exons. (B) Sequence alignments of IRF6 in various species. Note that the DNA-Binding domain (blue),
including the penta-tryptophan cluster (dark blue), and the SMIR/IAD (light red) are highly conserved. The dark red highlighted stretch indicates the newly generated
sequence due to the VWS-causing IRF6 variant. The numbers indicate the amino acids (aa). (C) Schematic representation of the IRF6 and the IRF6_VWS protein
p.(Val321Profs*15). Numbers indicate the aa. Note that IRF6_VWS is a truncated IRF6 variant that contains a unique stretch of 14 aa (box) at its C-terminus. ∗stop
codon.
suprabasal layers in the VWS culture compared to CLP1 and
CLP2 (Figures 1C, D).
Identification of a Novel IRF6 Variant
Causing VWS
Although the VWS keratinocytes displayed deficiencies
to terminally differentiate in vitro [Figure 1 and (Degen
et al., 2018)], the underlying VWS-causing variant in
the specific individual remained elusive. Targeted Exome
Sequencing (TES) identified the heterozygous frameshift
variant c.961_965delGTGTAinsC in IRF6. To the best of our
knowledge, this IRF6 variant is novel and has never been
described in the literature and is not listed in the Human
Gene Mutation Database [HGMD R© (Stenson et al., 2017)].
Both parents of the VWS patients are asymptomatic. However,
genetical analysis of their IRF6 genes could not be performed
to confirm a de novo origin of the variant in the patient. The
uncovered variant in our VWS individual affects exon 7 of
IRF6 (Figure 2A), which encodes for the highly conserved
SMIR/IAD (Figure 2B). Consequently, the variant results in a
predicted amino acid (aa) change at position 321 [p.(Val321Pro)]
followed by a frameshift leading to a truncated open reading
frame due to the presence of a premature termination codon
(PTC) [p.(Val321Profs∗15)] in exon 7 (Figures 2A, C). The
resulting altered IRF6_VWS protein is predicted to consist
of 334 aa only because it lacks the entire C-terminus and the
last 73 aa of the SMIR/IAD of the IRF6wt protein. Instead,
IRF6_VWS contains a unique C-terminal stretch of 14 aa
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(Figure 2C, red box). According to the ACMG-standards and
guidelines (Richards et al., 2015) this variant is classified as
likely pathogenic.
The IRF6_VWS mRNA Is Targeted by
NMD
The non-sense-mediated mRNA decay (NMD) mechanism is
known to degrade mRNAs containing PTCs in order to prevent
translation of aberrant transcripts (Wilusz et al., 2001; Maquat,
2002). Since our newly identified IRF6_VWS allele is transcribed
into a transcript with an NMD-triggering PTC [PTC is not
located in the last exon and is situated more than ≥ 50–
55 bp upstream of the last exon-exon junction (Kurosaki
and Maquat, 2016)] (Figure 2), we assessed the possibility
of IRF6_VWS mRNA being targeted and degraded by NMD.
Therefore, we compared the sequencing chromatograms around
the IRF6 variant at position c.961 from fragments that have
been amplified from RNA extracted from VWS and CLP1
keratinocytes. A mixed sequencing signal at the position of the
novel IRF6 variant (961 bp) was present in the VWS, but not
in the CLP1 keratinocytes (Figure 3A top panel). While the
prominent peaks of the chromatogram in VWS correspond to
the IRF6wt transcript sequence (GTGTA, Figure 3A black box,
top panel left), the overlapping smaller peaks additionally disclose
the discrete presence of the IRF6_VWS transcript sequence
(CCTGG, Figure 3A, red box, top panel left). This result
would imply that the vast majority (≈ 90%) of the IRF6_VWS
mRNA is degraded, but that a moderate amount of the VWS-
specific transcript remained expressed. To test this speculation
and to prove that NMD was the responsible mechanism for
the degradation of aberrant IRF6, we treated the cells with
puromycin, a known NMD inhibitor (Andreutti-Zaugg et al.,
1997). Addition of puromycin greatly rescued the diminished
levels of IRF6_VWS as evidenced by the increased peaks of the
mutated IRF6 sequence in the VWS keratinocytes (Figure 3A,
red box, bottom panel left). On the other hand, the addition
of puromycin did not affect IRF6 transcripts in CLP1. These
results prove that NMD is the responsible mechanism for
IRF6_VWS degradation.
We further wished to confirm the low expression level of
IRF6_VWS and its significant increase by inhibiting NMD in
VWS keratinocytes by qPCR and immunoblots. Using primers
that showed a higher affinity to anneal to the IRF6_VWS than
to the IRF6wt sequence (Figure 3B), we could reveal that
IRF6_VWS is expressed and detectable in VWS keratinocytes and
that blocking NMD by puromycin and cycloheximide (CHX)
significantly increased its levels (Figure 3C, top panel). As
expected, the IRF6_VWS transcript was not detectable in CLP1-
and healthy lip-derived keratinocytes. Total IRF6 (IRF6_VWS
and IRF6wt) and IRF6wt levels were reduced by 50% in VWS
compared to CLP1 and healthy lip keratinocytes. While this
reduction could be reversed by puromycin and CHX for total
IRF6, IRF6wt levels did not change in response to the NMD
inhibitors (Figure 3C, middle and bottom panels). These results
clearly indicate that more IRF6_VWS is being expressed in
the presence of the NMD inhibitors puromycin and CHX. In
agreement with these qPCR findings, we identified significantly
higher IRF6wt protein expression in CLP1 compared to VWS
keratinocytes, even in the presence of puromycin (Figure 3D).
Unfortunately, we are unable to detect the truncated IRF6_VWS
protein (≈ 50 kDa), likely due to its very low expression levels.
To extend these data, we screened IRF6 mRNA and protein
levels in keratinocytes derived from the VWS individual,
four non-syndromic CLP patients, and three healthy control
tissues (Table 1). While total IRF6 levels were significantly
reduced in VWS compared to all other primary cells tested
(Figure 4A), IRF6_VWS was only significantly detectable in
VWS keratinocytes (Figures 4B), which is consistent with our
previous results. Immunoblots confirmed lowest IRF6 protein
levels in VWS keratinocytes compared to the other cells tested
(Figure 4C), demonstrating that the novel VWS-causing IRF6
variant results in haploinsufficiency of IRF6 caused by NMD.
Lower Forced Expression of IRF6_VWS
Compared to That of IRF6wt
Since the NMD-dependent degradation of IRF6_VWS is not
100% efficient, a small amount of the aberrant transcript remains
expressed and detectable (Figures 3, 4). This prompted us to
investigate the molecular characteristics of the ectopically
expressed IRF6_VWS protein in HEK293, HaCaT and
OKF6/TERT2 cell lines. Using specific qPCR primers recognizing
exogenous IRF6wt and exogenous IRF6_VWS (Figure 5A), we
could readily notice robust expression of both IRF6wt and
IRF6_VWS in all three cell lines 24 h after transfection
(Figure 5B). In addition, while IRF6 was endogenously expressed
in HaCaT and OKF6/TERT2 cells, IRF6 could not be detected
in HEK293 cells (Figure 5B). Parallel cultures were analyzed
by immunoblots for IRF6 protein levels 24 and 48 h post-
transfection. IRF6wt was strongly over-expressed in all three cell
lines after 24 h and it was still prominently detectable after 48 h
(Figure 5C). In contrast, IRF6_VWS was only poorly expressed
24 h post-transfection and its forced expression was completely
lost after 48 h in HaCaT and OKF6/TERT2 cells (Figure 5C,
arrowheads and Supplementary Figure S1).
IRF6_VWS Is Mislocalized in Cells
Next we wanted to analyze the cellular localization of IRF6_VWS
in keratinocytes and whether its localization differs to the one
of IRF6wt. Exogenous IRF6wt was mostly found expressed in
the cytoplasm of both HaCaT and OKF6/TERT2 cells, which
is in agreement with its endogenous localization (Figure 6A).
The localization of IRF6_VWS was slightly different than its wt
counterpart as its weaker expression was detected more often
in the nucleus (Figure 6A and Supplementary Figure S2). To
clarify this initial observation, we analyzed 75 individual IRF6wt
and IRF6_VWS-transfected HaCaT cells for the localization of
exogenous IRF6. We used linescan plots and determined the
exogenous IRF6 signal intensity in the cytoplasm (c) and in the
nucleus (n) for each of the transfected cells. This allowed us
to calculate the c/n ratio for each individual cell, based upon
which we could define three different IRF6 localization patterns:
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FIGURE 3 | (A) Sanger DNA Sequencing chromatograms of the IRF6 sequence encompassing the VWS-causing IRF6 variant (VWS) and the same sequence in a
non-syndromic CLP patient (CLP1) in the absence or presence of the non-sense-mediated mRNA decay (NMD) mechanism inhibitor puromycin. Sequences of
interest are indicated by boxes. Black box: GTGTA-sequence of IRF6wt; red box: CCTGG-sequence of the IRF6_VWS. Note that blocking NMD by puromycin
results in more pronounced IRF6_VWS sequencing peaks in the VWS sample. (B) Schematic representation of the IRF6wt and IRF6_VWS gene with the specific
qPCR primers used. Light gray boxes: untranslated exons/regions; dark gray boxes: translated exons; red box: location of mutation and novel sequence. (C) qPCR
analysis of IRF6 expression in VWS (black), CLP1 (white), and healthy lip keratinoctyes (gray) in the absence or presence of puromycin and CHX. Note that IRF6_VWS
is detectable by qPCR and that its levels increase in the presence of both NMD inhibitors, puromycin and CHX (top panel). Also note that IRF6wt levels are higher in
CLP1 and healthy lip than in VWS (bottom panel). *p ≤ 0.05. (D) Immunoblots of protein extracts from VWS (black) and CLP1 (white) keratinocytes in the absence or
presence of puromycin for endogenous IRF6. Note that IRF6wt levels are lower in VWS when compared to CLP1 cells and that the endogenous IRF6_VWS is not
detectable in the VWS cells. Quantification of IRF6wt levels is shown at the bottom. ∗p ≤ 0.05. The full-length blots are presented in Supplementary Figure S6.
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FIGURE 4 | (A) qPCR analysis of IRF6wt in VWS-keratinocytes (VWS, black), four non-syndromic CLP-keratinocytes (CLP1-4, white) and healthy control
keratinocyte cultures (lip, forehead, and foreskin; gray). Note lowest levels of IRF6wt in VWS compared to the others. *p ≤ 0.05 vs. CLP1-4, lip, forehead, foreskin.
(B) qPCR analysis of IRF6_VWS in the same keratinocyte cultures. Note that IRF6_VWS is only robustly expressed in VWS. *p ≤ 0.05 vs. CLP1-4, lip, forehead,
foreskin. (C) Immunoblot of the corresponding protein extracts for IRF6 and its densitometric quantification. Note low endogenous IRF6wt protein levels in VWS and
that IRF6_VWS, which runs at about 50 kDa, cannot be detected in VWS. ∗p ≤ 0.05 vs. CLP1-4, lip, forehead, foreskin. The full-length blots are presented in
Supplementary Figure S6.
Type 1, c/n ≥ 1.2 (mostly cytoplasmic); Type 2, c/n = 0.8–
1.2 (within all the cell); Type 3, c/n ≤ 0.8 (mostly nuclear).
Representative linescan plots of the three IRF6 localization
types and the corresponding immunostainings of IRF6_VWS-
transfected cells are shown in Figure 6B. Our analysis revealed
a significant lower mean c/n ratio in cells transfected with
IRF6_VWS than with IRF6wt (Figure 6C), suggesting enhanced
nuclear presence of IRF6_VWS, which is in agreement with our
initial visual observations. While 80% of the IRF6wt-transfected
cells exclusively expressed IRF6wt in the cytoplasm (Type 1), the
majority (80%) of ectopic IRF6_VWS was found in the nucleus
(Type 2 and 3) of transfected cells (Figure 6D).
IRF6_VWS Is Less Stable Than IRF6wt
Our observations of consistently weaker expression of exogenous
IRF6_VWS compared to IRF6wt (Figures 5C, 6A) prompted us
to test the hypothesis that IRF6_VWS is less stable than IRF6wt.
Therefore, we used a CHX chase assay to follow the levels (≈
stability) of the two proteins. As shown in Figure 7A (left panels),
immunoblots of cell lysates revealed that exogenous IRF6wt
levels remained stable within eight hours of CHX treatment in
all cell lines tested. In contrast, IRF6_VWS levels were already
significantly reduced in the presence of CHX after two hours
and almost absent after eight hours (Figure 7A, arrowheads,
right panels). Quantification of the blots disclosed a half-life for
IRF6_VWS of two hours in the two keratinocyte cell lines, and
of around seven hours in HEK293 cells (no endogenous IRF6)
(Figure 7B and Supplementary Figure S3).
Next, we tested whether inhibiting the proteasome system
could prevent the rapid degradation of IRF6_VWS observed after
CHX treatment. IRF6_VWS transfected cells were either treated
with the proteasome inhibitor MG132 and CHX alone or in
combination for eight hours. Immunoblot analysis demonstrated
that MG132 was able to significantly inhibit CHX-mediated
degradation of IRF6_VWS in all cell lines tested (Figure 7C,
arrowheads), suggesting that IRF6_VWS is degraded in a
proteasome-dependent manner. Consistently, almost all cell lines
showed a moderate increase of IRF6_VWS in response to MG132
(Figure 7C and Supplementary Figure S4).
IRF6_VWS Maintains Transcription
Factor Function
Finally, we aimed to study whether IRF6_VWS, although lacking
part of its SMIR/IAD, can still act as a transcription factor and
regulate gene expression. Initially, we used a luciferase assay
approach and could show that both IRF6wt and IRF6_VWS
were able to activate an Interferon-β promoter construct
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FIGURE 5 | (A) Schematic representation of the cloned, exogenous IRF6wt and IRF6_VWS and the primers used to specifically detect them. Gray boxes: translated
exons; red box: IRF6_VWS specific mutation; blue box: myc tag; exo.: exogenous. (B) qPCR analyses of total IRF6 (top), exo. IRF6wt (middle), and exo. IRF6_VWS
(bottom) in transiently transfected HEK293, HaCaT and OKF6/TERT2 cells 24 h post-transfection. #not detectable (Ct values > 32). (C) Immunoblots of transiently
transfected HEK293 (top), HaCaT (middle), and OKF6/TERT2 (bottom) 24 and 48 h after transfection with an anti-IRF6 and an anti-myc antibody. Note that while
IRF6wt runs at 60 kDa, IRF6_VWS is weakly expressed at 50 kDa (arrowhead). ∗background band. The full-length blots are presented in Supplementary Figure S6.
(Supplementary Figure S5). However, at the end we were keen
to learn whether IRF6_VWS was able to modulate endogenous
target gene expression. Although, IRF6 is known to regulate
epidermal differentiation, forced expression of neither IRF6wt
nor IRF6_VWS was sufficient to induce the late differentiation
markers LOR and FLG (Figure 8A), which is in agreement with a
study performed in mice (Biggs et al., 2012). However, we found
significant induction of endogenous IRF6 itself, GRHL3, KLF4,
and OVOL1 in response to both ectopic IRF6wt and IRF6_VWS
expression (Figure 8B). All of these transcription factor genes
have been reported to be direct IRF6 targets (Botti et al., 2011;
de La Garza et al., 2013; Liu et al., 2016), which is in line
with our own data (Figure 8B). We validated some of these
results on protein levels by immunoblotting for IRF6 and KLF4.
Forced expression of IRF6_VWS, as evidenced by the presence
of the truncated IRF6_VWS protein at 50 kDa (arrowhead), as
well as ectopic IRF6wt expression resulted in increased levels
of endogenous IRF6 at 60 kDa and of KLF4 (Figures 8C, D).
Generally, the mRNA and protein induction in response to forced
IRF6_VWS expression was slightly lower than the one to IRF6wt
(Figures 8B, D). Still, our data demonstrate that IRF6_VWS
maintains transcription factor function.
DISCUSSION
The basis for this study was our previous work that showed
variations in the potential to terminally differentiate among CLP-
derived keratinocytes. One patient whose keratinocytes exhibited
defects in the epidermal differentiation program presented with
lower lip pits and CLP, strong clinical diagnostic criteria for
VWS (Rizos and Spyropoulos, 2004; Degen et al., 2018). With
an estimated frequency of about one in 35’000 newborns,
VWS is a very rare syndrome (Dixon et al., 2011). Hence, the
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FIGURE 6 | (A) HaCaT and OKF6/TERT2 cells were transiently transfected with pCMV6, IRF6wt, and IRF6_VWS and stained with an anti-myc and anti-IRF6
antibody to analyze the localization of the exogenous proteins. Scale bar: 20 µm. Endogenous IRF6 was weakly detectable in both cell lines (pCMV6/anti-IRF6
panels) and is shown for HaCaT cells as a close-up (longer exposure). Scale bar: 10 µm. Note that IRF6_VWS was weaker expressed than IRF6wt. (B)
Representative linescan plots (blue: DAPI/nucleus channel; green: FITC/IRF6 channel) of individual cells (left) describing the following three types of IRF6 localization:
Type 1: c/n ≥ 1.2; Type 2: c/n = 0.8–1.2; Type 3: c/n ≤ 0.8 (middle). C: cytoplasmic intensity; n: nuclear intensity. Matching IRF6 localizations for each of the three
categories are shown as pictures of anti-myc immunostained IRF6-transfected HaCaT cells (right). Scale bar: 10 µm. (C) Dot plots summarizing the analysis of 75
individual IRF6wt- and IRF6_VWS-transfected HaCaT cells by linescan plots showing the c/n ratio. Note that in IRF6_VWS-transfected cells there is a prominent
fraction of cells with a ratio c/n ≤ 0.8 (Type 3). ∗p ≤ 0.001. (D) Relative distribution of exogenous IRF6 localization within transfected HaCaT cells. Note that while
most (≈ 80%) of the IRF6wt is localized in the cytoplasm (Type 1: c/n ≥ 1.2), most (≈ 50%) of the IRF6_VWS is found in the nucleus (Type 3: c/n ≤ 0.8).
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FIGURE 7 | (A) Immunoblots of IRF6 in IRF6wt- and IRF6_VWS-transfected HEK293, HaCaT, and OKF6/TERT2 cells treated with the protein synthesis inhibitor
cycloheximide (CHX). While IRF6wt was stable within 8 h of CHX treatment, IRF6_VWS levels were greatly reduced. ∗background band. Arrowheads: IRF6_VWS. (B)
Quantification of the immunoblots (anti-myc antibody) confirms that IRF6_VWS (black) is less stable than IRF6wt (gray). (C) Immunoblots of IRF6_VWS-transfected
cells in the presence of the proteasome inhibitor MG132, CHX, and combination of MG132/CHX for levels of IRF6_VWS. ∗background band. The quantifications of
the immunoblots are shown below. Note that presence of MG132 greatly diminishes the effect of CHX on IRF6_VWS. ∗p ≤ 0.05. Arrowheads: IRF6_VWS. The
full-length blots are presented in Supplementary Figure S6.
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FIGURE 8 | (A) qPCR analysis for endogenous LOR and FLG in HaCaT cells transfected with IRF6wt and IRF6_VWS 24 h after transfection. Note that neither LOR
nor FLG are induced by forced expression of IRF6. (B) qPCR analysis of endogenous IRF6, GRHL3, KLF4, and OVOL1 in HaCaT cells in response to IRF6wt and
IRF6_VWS over-expression. *p ≤ 0.05 vs. IRF6wt, IRF6_VWS. Note that the forward primer for the detection of endogenous IRF6 using qPCR was designed to
amplify the non-coding 5’UTR region of the IRF6 gene. (C) Immunoblots for endogenous IRF6 and KLF4 in HaCaT cells transfected with IRF6wt and IRF6_VWS.
Note that IRF6_VWS is able to induce these proteins, although a little less effective than IRF6wt. ∗background band. Arrowheads: IRF6_VWS. The full-length blots
are presented in Supplementary Figure S6. (D) Quantification of the immunoblots. ∗p ≤ 0.05 vs. IRF6wt, IRF6_VWS.
availability and the possibility to work with VWS patient-derived
keratinocytes, which are isolated from the site of the orofacial
defect collected during primary lip repair, is infrequent and
makes our study very unique and relevant. Using a combinatorial
approach of genetics as well as molecular and cellular tools, we
present data on the mechanism by which a novel pathogenic IRF6
variant causes VWS.
The VWS locus was initially mapped to chromosome 1q32-41
(Murray et al., 1990; Schutte et al., 2000) and the gene encoding
for the transcription factor IRF6 was later found to be mutated in
most of the VWS cases (Kondo et al., 2002). Genetic analysis of
our VWS individual revealed a novel VWS-causing IRF6 variant
c.961_965delGTGTAinsC/p.(Val321Profs∗15). According to
HGMD R© (Stenson et al., 2017), there are currently 351 described
pathogenic IRF6 variants that either cause non-syndromic CLP,
or the rare diseases Pierre Robin Sequence (OMIM # 261800),
VWS or the related PPS. These pathogenic variants are non-
randomly distributed among the nine exons of IRF6 as most of
them are localized within its two conserved functional domains,
the DBD (aa 13-113, exons 3–4) and the SMIR/IAD (aa 226-394,
exons 7–8). Whereas the distribution of the IRF6 variants
associated with VWS are balanced between the two important
domains of IRF6, most of the missense variants causing PPS
are present within the DBD (Kondo et al., 2002). Our newly
identified IRF6 pathogenic variant is located in the SMIR/IAD
(Figure 2) and results in a truncated version of IRF6, lacking its
C-terminus, which contains two phosphorylation sites at Ser413
and Ser424 important for IRF6 activation (Chen et al., 2008;
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Tamura et al., 2008; Oberbeck et al., 2019). Based on the
observations that IRF6 truncations are more common in
VWS than in PPS (Kondo et al., 2002; de Lima et al., 2009)
and that deletions within the VWS locus have already been
described a long time ago in VWS-affected families (Bocian
and Walker, 1987; Schutte et al., 1999; Osoegawa et al., 2008),
haploinsufficiency of IRF6 is assumed to be the reason for
IRF6-caused VWS. Using our patient-derived keratinocytes,
we could prove that our newly discovered pathogenic IRF6
variant indeed results in haploinsufficiency of IRF6 in the VWS
keratinocytes (Figure 4). IRF6_VWS mRNA undergoes an
NMD process, which markedly degrades the aberrant transcript
(Figure 3). NMD is a cellular surveillance pathway that reduces
gene expression by eliminating mRNA transcripts containing
premature PTCs (Schweingruber et al., 2013). The ability to
discriminate PTC-containing mRNA in mammalians from
mRNAs with normal termination codons is dependent on the
position of the PTC within the mRNA. Mutant transcripts with
a PTC in the last exon, or within 50–55 bp upstream of the
last exon-exon junction are not recognized as NMD substrates
and truncated mutant proteins are expected to be translated
from these aberrant mRNAs. In contrast, a PTC that is not
located in the last exon, or more than 50–55 bp upstream of
the last exon-exon junction is recognized and degraded by the
NMD process (Nagy and Maquat, 1998; Byers, 2002; Kurosaki
and Maquat, 2016; Popp and Maquat, 2016). Our identified
pathogenic IRF6 variant results in a PTC that is situated in the
third last exon (exon 7) and more than 50–55 bp upstream
from the last exon-exon junction. Hence, the PTC in our
novel IRF6 variant adheres to the rules of NMD. Notably,
NMD can be beneficial for us by eliminating the synthesis
of C-terminally truncated proteins with dominant-negative
effects. However, if the truncated protein encoded by the PTC-
containing mRNA remains some residual physiological function,
NMD-mediated degradation of mRNA abundance might
cause more clinical problems than benefits (Schweingruber
et al., 2013). These circumstances reflect the situation in
our VWS case: (1) the aberrant IRF6 transcript contains an
NMD-triggering PTC in the third last exon (exon 7) of IRF6
(Figure 2) and (2) the IRF6_VWS protein still harbors some
physiological transcription factor activity as it is able to induce
the endogenous transcription factors GRHL3, KLF4, and OVOL1
as well as IRF6 itself (Figure 8). There is increasing evidence
that a IRF6 threshold level is required for its full physiological
activity during craniofacial development (Ingraham et al., 2006;
Richardson et al., 2006), neurulation (Kousa et al., 2019), and
keratinocyte migration and wound healing (Rhea et al., 2020).
Therefore, the efficiency of the NMD process might be a crucial
modulator of the clinical manifestation of VWS, a condition
often associated with truncating IRF6 variants (de Lima et al.,
2009). A less effective NMD in our VWS individual would
result in an increased amount of aberrant IRF6_VWS mRNA
and consequently, to higher levels of IRF6_VWS protein, which
maintains some transcription factor function (Figure 8). This
increase in IRF6 protein levels might be enough to reach the IRF6
threshold required for its proper functioning. However, since
VWS represents a developmental malformation and NMD is an
important regulator of many physiological mRNAs, therapeutic
treatments to suppress translation termination at the PTC,
allowing the generation of a truncated IRF6_VWS protein, are
not feasible (Hwang and Maquat, 2011; Huang and Wilkinson,
2012; Karam et al., 2013; Kurosaki and Maquat, 2016).
IRF6 regulates the balance between keratinocyte
proliferation/differentiation. Irf6-deficient mice exhibit a
hyperproliferative epidermis that fails to undergo terminal
differentiation leading to defects during craniofacial development
(Kondo et al., 2002; Ingraham et al., 2006; Richardson et al.,
2006). These IRF6-related phenotypes have been recently
confirmed in humans using skin biopsies as well as keratinocytes
isolated from the hip region of VWS patients harboring IRF6
variants (Hixon et al., 2016). These observations are in agreement
with our own results using primary VWS lip keratinocytes, which
exhibit a higher proliferation rate (Degen et al., 2018) and defects
in terminal differentiation (Figure 1). For the first time, we
used such primary CLP patient-derived keratinocytes in 3D-skin
models. We could show that both the VWS- and non-syndromic
CLP-derived keratinocytes were able to differentiate, with
no obvious morphological differences, as evidenced by H&E
staining. This apparent discrepancy to the in vivo situation
in VWS skin tissues [e.g., thicker epidermis in VWS patients
compared to non-syndromic CLP patient (Hixon et al., 2016)]
might reflect the technical limits of in vitro 3D-cultures, which
still represent very simplified skin models. Yet, we uncovered
subtle defects in the late epidermal differentiation program in
VWS-derived keratinocytes compared to CLP keratinocytes,
such as reduced levels of LOR in 3D-skin models (Figure 1).
The pathogenic IRF6 variant (c.961_965delGTGTAinsC)
results in IRF6_VWS being expressed at significantly reduced
levels compared to IRF6wt due to reduced protein stability
(Figure 7). Similar results have been reported for another VWS-
causing IRF6 variant, p.(Arg412X) (Kwa et al., 2015). This
observation might be explained by studies on the structure of
IRF3 showing that the IAD forms a condensed hydrophobic core
with its flanking autoinhibitory elements, which is then bound
by the DBD resulting in a compact structure of IRF3 (Qin et al.,
2003). IRF6 is known to be similarly inhibited by autoinhibitory
elements located in its C-terminal domain (Little et al., 2009).
Hence, lack of the C-terminus of IRF6, as is the case in our VWS
patient, might lead to a relatively open and extended structure of
IRF6 that is prone to degradation (Kwa et al., 2015). We further
show that degradation of IRF6_VWS is proteasome-dependent,
an observation that is also supported by other studies (Bailey
et al., 2008; Kwa et al., 2015).
Endogenous IRF6 as well as exogenous IRF6wt are mostly
localized in the cytoplasm of cells. This is in contrast
to IRF6_VWS, which was often detected in the nucleus
(Figure 6). However, the biological consequences of this apparent
mislocalization remain to be determined. Latent transcription
factors often reside in the cytoplasm and translocate to the
nucleus upon specific external stimuli. This shuttling requires
nuclear localization signals (NLS), nuclear export signals (NES),
and binding of chaperones. To our knowledge, such signals
and chaperones have not been identified and verified for IRF6
so far. We can only speculate about the reasons for our
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observation of enhanced nuclear presence of IRF6_VWS: (1)
there is a NES present in the C-terminal region of IRF6
that is missing in our VWS patient due to the gene variant;
(2) nuclear export of IRF6 might depend on certain proteins
(chaperones) that interact with and guide IRF6 out of the
nucleus. The truncating IRF6 variant might abolish these binding
sites, which results in more nuclear IRF6_VWS; (3) the newly
generated very C-terminal aa sequence of IRF6_VWS, as a
result of the mutation, mimics a new NLS, which shifts the
steady state equilibrium to the nucleus; (4) posttranslational
modifications (e.g., phosphorylations, glycosylations) within the
missing sequence of IRF6_VWS are required for nuclear export.
Clearly, our initial observations warrant further studies to exactly
elucidate the shuttling of IRF6 in and out of the nucleus.
In summary, we identified a novel pathogenic IRF6
variant c.961_965delGTGTAinsC/p.(Val321Profs∗15) in a VWS
individual and show how this IRF6 variant is regulated by
an NMD process and affects the phenotype of keratinocytes:
most of the IRF6_VWS mRNA is subject to NMD, resulting
in reduced IRF6 levels (haploinsufficiency). The minor amount
of IRF6_VWS that is not degraded by NMD is translated into
a functional transcription factor that can still regulate GRNs
important for epidermal differentiation such as GRHL3, KLF4,
OVOL1, and IRF6 (Figure 8). However, a greatly accelerated
IRF6_VWS turnover as well as protein mislocalization further
complicate proper IRF6 function. At the end, IRF6 is not present
at the required threshold level to be able to properly fulfill
all its important activities. Such defects might be reflected in
phenotypic changes in cells during development, such as reduced
formation of the periderm, whose structure is dependent on
IRF6 function (Richardson et al., 2009, 2014). An improperly
arranged and harmed periderm cannot prevent pathological
epithelial fusions between different tissues in the oral cavity
anymore (Hammond et al., 2019), which might explain the
clinical clefting manifestation in our VWS individual. Finally,
our study not only contributes to the advancement of knowledge
on IRF6 function in health and disease, but also promotes the
following idea: although the use of postnatal tissue to study CLP
that arises early in development comes with some challenges and
assumptions, various cellular and molecular properties persist
postnatally in CLP patient-derived cells, which makes studies
using such primary cells very unique and clinically relevant.
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Supplementary Figure 1. Quantification of the relative IRF6 levels from the immunoblots in 
HEK293, HaCaT, and OKF6/TERT2 cells transfected with IRF6wt (white) and IRF6_VWS (black). 
* p ≤ 0.05 vs. IRF6wt (24 h / 48 h); # not detectable. 
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Supplementary Figure 2. A representative image of HaCaT cells transfected with the IRF6_VWS 
construct stained with the anti-myc antibody. Indicated are the three types of cellular IRF6_VWS 
localization as assessed by linescan plots. Scale bar: 50 µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. Quantification (of anti-IRF6 immunoblots) of the relative IRF6wt (gray) 
and IRF6_VWS (black) levels in HEK293, HaCaT, and OKF6/TERT2 cells transfected with IRF6wt 
and IRF6_VWS, respectively, and treated with cycloheximide (CHX).  
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Supplementary Figure 4. Densitometric quantification of the relative IRF6_VWS levels in 
HEK293, HaCaT, and OKF6/TERT2 cells transfected with IRF6_VWS and treated with either 
MG132, CHX, or MG132/CHX (anti-IRF6 immunoblots). * p ≤ 0.05.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5. HEK293T cells were transfected with an IFNβ promoter reporter plasmid 
together with plasmids expressing IRF6wt and IRF6_VWS. Gene reporter activity was measured 24 
h post-transfection and is shown as the fold increase over cells transfected with empty plasmid. * p ≤ 
0.05 vs. IRF6wt, IRF6_VWS. 
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Supplementary Figure 6. Full-length blots of the immunoblot analyses of Figures 3, 4, 5, 7 and 8 
are shown. * background bands. 
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1.2 Supplementary Tables 
 
 
Supplementary Table 1. Sequence of the qPCR primers used in this study. bp: base pairs 
 
 
 
 
 
